Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Looking for participantsNCT04162353
What this trial is testing

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Very early researchLooking for participantsNCT04603872
What this trial is testing

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryAcute Lymphoblastic Leukemia, in Relapse+3 more
Zhejiang University 120
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Very early researchUnknownNCT04412889
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Who this might be right for
Multiple Myeloma
Hebei Yanda Ludaopei Hospital 18
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Very early researchUnknownNCT04182581
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xijing Hospital 18
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Very early researchLooking for participantsNCT06976437
What this trial is testing

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Who this might be right for
B Cell LymphomaMultiple Myeloma
YANRU WANG 21
Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)UnknownNCT04714827
What this trial is testing

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanxi Province Cancer Hospital 24